Market Research Industry Today
Dilated Cardiomyopathy Therapeutics Market to Decline at -7.0% CAGR from 2014-2020 owing to the Availability of Implantable Devices
A new market report published by Transparency Market Research is Dilated Cardiomyopathy Therapeutics Market [Drug Class: Aldosterone Antagonists, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs) and Beta-Blockers] - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
Published 15 September 2015
The Global dilated cardiomyopathy (DCM) market was estimated at US$651.0 million in 2013 and is expected to reach US$328.6 million in 2020, declining at a -7.0% CAGR between 2014 and 2020.The rising incidence of congestive heart failure is the lone major driver for the market for cardiomyopathy therapeutics, but there are a number of factors that impede the growth of the market in the coming future. The availability of implantable devices, such as heart pumps, implantable cardioverter defibrillators (ICDs), and pacemakers, and the propitious development of gene therapy will hamper the growth of the dilated cardiomyopathy therapeutics market in the coming future. Additionally, the numerous side effects related to the usage of DCM drugs and the easier treatment with the help of other devices, which have minimal or nil side effects, will impede the growth of this market in the forthcoming future.
In terms of drug class, the dilated cardiomyopathy therapeutics market is segmented into angiotensin-converting enzyme (ACE) inhibitors, aldosterone antagonists, beta blockers, and angiotensin II receptor blockers (ARBs). Amongst these, in 2013, ARBs held the biggest revenue share in the market, trailed by beta blockers. The reason for them acquiring the biggest revenue share is their high demand in dilated cardiomyopathy treatment, particularly in the developed regions of Europe and North America. On the other hand, the aldosterone antagonists segment held the highest growth rate owing to the positive affect of the combination of aldosterone antagonists with ACE inhibitors or ARBs for reducing the progress of Duchenne muscular dystrophy (DMD).
In terms of pipeline drugs, the dilated cardiomyopathy therapeutics market is segmented into ixCELL-DCM, ARRY-797, OR, MYDICAR, and CAP-1002. The key companies prevalent in the market have introduced clinical trials to make these therapeutics effective at treating dilated cardiomyopathy. If these clinical studies succeed, then the demand for dilated cardiomyopathy therapeutics market might increase in the forthcoming future.On the basis of geography, the dilated cardiomyopathy therapeutics market is segmented into Europe, North America, Asia Pacific, and the Rest of the World (RoW). In 2013, North America held the biggest share in the market due to the increased acceptance of branded drugs and the increasing occurrence of congestive heart failure. DCM occurs in around 5 to 8 people amongst every 100,000 people in the U.S. The markets in Asia Pacific and the Rest of the World (RoW) are the most swiftly developing markets owing to increasing disposable income of patients in these regions, consistently growing demand for generic drugs, and increasing economic standards.AstraZeneca plc, Array BioPharma, Inc., Celladon Corporation, Janssen Pharmaceuticals, Inc., GlaxoSmithKline plc, Merck & Co., Inc., Pfizer, Inc., Novartis International AG, Sanofi S.A., Vericel Corporation, and Teva Pharmaceutical Industries Ltd. are amongst the prime players in the dilated cardiomyopathy therapeutics market.
Browse the full Dilated Cardiomyopathy Therapeutics Market [Drug Class: Aldosterone Antagonists, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs) and Beta-Blockers] - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 report at http://www.transparencymarketresearch.com/dilated-cardiomyopathy-market.html
The global dilated cardiomyopathy therapeutics market is segmented into the following categories:
Dilated cardiomyopathy therapeutics market, by drug class
- Aldosterone antagonists
- Angiotensin-converting enzyme (ACE) inhibitors
- Angiotensin II receptor blockers (ARBs)
- Beta-blockers
Dilated cardiomyopathy therapeutics market, by pipeline drugs
- ARRY-797
- ixCELL-DCM
- MYDICAR
- OR-1
- CAP-1002
Dilated cardiomyopathy therapeutics market, by geography
- North America
- Europe
- Asia Pacific
- Rest of the World (RoW)
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Contact
Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Share on Social Media
Contact Information
Mr. Rohit Bhisey
Transparency Market Research
State Tower, 90 State Street,
Suite 700,
Albany
12207
+91- 8600924083
http://www.transparencymarketresearch.com/
Other Industry News
Ready to start publishing
Sign Up today!
